Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | B3GNT2 | Q9NY97 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.45 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21156818 | 0.87 | LMNA (0.51) | B3GNT2LMNAPGRMAOBDAO | |
| SCHEMBL1759317 | 0.87 | ALDH1A1 (0.52) | B3GNT2LMNAAURKAKDM4EALDH1A1 | |
| SCHEMBL29670373 | 0.87 | ALDH1A1 (0.52) | B3GNT2LMNAAURKAKDM4EALDH1A1 | |
| SCHEMBL25195141 | 0.85 | LMNA (0.50) | B3GNT2LMNAAURKAPGRKDM4E | |
| SCHEMBL6763764 | 0.85 | BRD4 (0.57) | B3GNT2LMNAPGRKDM4EALDH1A1 | |
| SCHEMBL29997137 | 0.84 | PGR (0.65) | B3GNT2LMNAPGRMAOBGAA | |
| SCHEMBL1759187 | 0.83 | CREBBP (0.51) | B3GNT2LMNAPGRKDM4EALDH1A1 | |
| SCHEMBL6763505 | 0.83 | AURKA (0.56) | B3GNT2LMNAAURKAPGRMAOB | |
| SCHEMBL12673423 | 0.83 | B3GNT2 (0.49) | B3GNT2LMNAPGRMAOBDAO | |
| SCHEMBL30593445 | 0.81 | LMNA (0.46) | B3GNT2LMNAPGRMAOBDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102633-B2 | Spirolactone compounds | QUIXGEN, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-3644998-B1 | NOVEL SPIROLACTONE COMPOUNDS | QUIXGEN INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230355609-A1 | Spirolactone Compounds | QUIXGEN, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| CN-110799187-B | Spirolactone compounds | 汇科锦公司 | 2023-10-03 | — | — | CN | disclosed |
| US-11541046-B2 | Spirolactone compounds | QUIXGEN, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | Janssen Biopharma, Inc. (US) | 2022-11-17 | — | — | US | disclosed |
| CN-114716426-A | Antiviral compounds | 詹森生物制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-105636936-B | Antiviral compounds | 詹森生物制药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3353180-B1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN LA ROCHE (CH) | 2022-03-16 | — | — | EP | disclosed |
| EP-3353176-B1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN LA ROCHE (CH) | 2022-01-19 | — | — | EP | disclosed |
| WO-2011058473-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058473-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058474-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058474-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC | 2011-05-12 | — | — | US | disclosed |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC | 2011-05-12 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1716100-A2 | THERAPEUTIC AMIDE DERIVATIVES | Pfizer, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005058304-A1 | IMPLANTABLE DEVICE CONTAINING INHIBITOR OF MACROPHAGE MIGRATION INHIBITORY FACTOR | CORTICAL PTY LTD (AU) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541046-B2 | Spirolactone compounds | ACACA, AKR1C2, AKR1A1 | B3GNT2 527/4885LMNA 3974/4885AURKA 1121/4885 |
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | B3GNT2 546/4885LMNA 4506/4885AURKA 1075/4885 |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | B3GNT2 440/4885LMNA 2437/4885AURKA 354/4885 |
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | B3GNT2 2579/4885LMNA 2978/4885AURKA 3571/4885 |
| US-20230355609-A1 | Spirolactone Compounds | ACACA, AKR1C2, AKR1A1 | B3GNT2 527/4885LMNA 3974/4885AURKA 1121/4885 |
| US-12102633-B2 | Spirolactone compounds | ACACA, AKR1C2, AKR1A1 | B3GNT2 527/4885LMNA 3974/4885AURKA 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.